{
    "root": "466b324b-711c-4088-a2a5-8b9f64fb7b92",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SUTENT",
    "value": "20250321",
    "ingredients": [
        {
            "name": "SUNITINIB MALATE",
            "code": "LVX8N1UT73",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232546"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE K25",
            "code": "K0KQV10C35",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        }
    ],
    "indications": {
        "text": "sutent kinase inhibitor indicated : \u2022 treatment adult patients gastrointestinal stromal tumor ( gist ) disease progression intolerance imatinib mesylate . ( 1.1 ) \u2022 treatment adult patients advanced renal cell carcinoma ( rcc ) . ( 1.2 ) \u2022 adjuvant treatment adult patients high risk recurrent rcc following nephrectomy . ( 1.3 ) \u2022 treatment progressive , well-differentiated pancreatic neuroendocrine tumors ( pnet ) adult patients unresectable locally advanced metastatic disease . ( 1.4 )",
        "doid_entities": [
            {
                "text": "gastrointestinal stromal tumor (DOID:9253)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9253"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "renal cell carcinoma (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "gist advanced rcc : \u2022 recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) . ( 2.1 ) adjuvant treatment rcc : \u2022 recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) maximum 9 cycles . ( 2.2 ) pnet : \u2022 recommended 37.5 mg orally daily . ( 2.3 )",
        "doid_entities": [
            {
                "text": "gist (DOID:9253)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9253"
            },
            {
                "text": "rcc (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sutent 12.5 mg capsules supplied hard gelatin capsule orange cap orange body , printed white ink `` pfizer `` cap , `` stn 12.5 mg `` body : bottles 28 capsules : ndc 0069-0550-38 sutent 25 mg capsules supplied hard gelatin capsule caramel cap orange body , printed white ink `` pfizer `` cap , `` stn 25 mg `` body : bottles 28 capsules : ndc 0069-0770-38 sutent 37.5 mg capsules supplied hard gelatin capsule yellow cap yellow body , printed black ink `` pfizer `` cap , `` stn 37.5 mg `` body : bottles 28 capsules : ndc 0069-0830-38 sutent 50 mg capsules supplied hard gelatin capsule caramel cap caramel body , printed white ink `` pfizer `` cap , `` stn 50 mg `` body : bottles 28 capsules : ndc 0069-0980-38",
    "adverseReactions": "none .",
    "indications_original": "SUTENT is a kinase inhibitor indicated for: \u2022 treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) \u2022 treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) \u2022 adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) \u2022 treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )",
    "contraindications_original": "GIST and Advanced RCC : \u2022 The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC : \u2022 The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET : \u2022 The recommended dosage is 37.5 mg orally once daily. ( 2.3 )",
    "warningsAndPrecautions_original": "SUTENT 12.5 mg capsules are supplied as hard gelatin capsule with orange cap and orange body, printed with white ink \"Pfizer\" on the cap, \"STN 12.5 mg\" on the body:\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 28 capsules:\u00a0\u00a0\u00a0NDC 0069-0550-38\n                  SUTENT 25 mg capsules are supplied as hard gelatin capsule with caramel cap and orange body, printed with white ink \"Pfizer\" on the cap, \"STN 25 mg\" on the body:\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 28 capsules:\u00a0\u00a0\u00a0NDC 0069-0770-38\n                  SUTENT 37.5 mg capsules are supplied as hard gelatin capsule with yellow cap and yellow body, printed with black ink \"Pfizer\" on the cap, \"STN 37.5 mg\" on the body:\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 28 capsules:\u00a0\u00a0\u00a0NDC 0069-0830-38\n                  SUTENT 50 mg capsules are supplied as hard gelatin capsule with caramel cap and caramel body, printed with white ink \"Pfizer\" on the cap, \"STN 50 mg\" on the body:\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 28 capsules:\u00a0\u00a0\u00a0NDC 0069-0980-38",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "SUTENT",
            "drugbank_id": "https://go.drugbank.com/drugs/DB18841"
        }
    ]
}